Jefferies Group’s Ultragenyx Pharmaceutical RARE Stock Holding History

Jefferies Group’s Portfolio RARE Stock Details RARE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-20,000	Closed	-$889K	–	1914
2020 Q1	$889K	Hold	20,000	–	–	0.01%	1070
2019 Q4	$854K	Buy	+20,000	New	+$825K	0.01%	1551
2016 Q4	–	Sell	-4,000	Closed	-$284K	–	2425
2016 Q3	$284K	Hold	4,000	–	–	﹤0.01%	1828
2016 Q2	$196K	Buy	+4,000	New	+$259K	﹤0.01%	1825
2015 Q4	–	Sell	-39,700	Closed	-$3.82M	–	2511
2015 Q3	$3.82M	Buy	+39,700	New	+$4.55M	0.02%	607

Other funds holding RARE

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Alkeon Capital Management New York $59.5B AUM 51.63% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Jefferies Group's RARE Position: Q2 2021 in Review

Jefferies Group sold out of Ultragenyx Pharmaceutical (RARE) in Q2 2021, closing a stake of 12,133 shares — an estimated $1.38M sold.

Jefferies Group first reported a position in RARE in Q3 2015 and held it in 5 quarters. The position peaked at $1.38M in Q1 2021. 241 funds tracked by Wall St. Rank hold RARE as of Q2 2021.

Jefferies Group reported no remaining Ultragenyx Pharmaceutical position as of Q2 2021 after selling out during the quarter.
Jefferies Group sold 12,133 Ultragenyx Pharmaceutical shares in Q2 2021, an estimated $1.38M.
Jefferies Group first reported a position in Ultragenyx Pharmaceutical in Q3 2015 and held it in 5 quarters.
Jefferies Group's Ultragenyx Pharmaceutical position peaked at $1.38M in Q1 2021.
241 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q2 2021.

Based on Jefferies Group's 13F filing for Q2 2021, filed 16 Aug 2021.